Stockscreener 앱 받기
78.19
2.05%
1.57
시장 영업 전:
78.44
0.25
+0.32%
전일 마감가:
$76.62
열려 있는:
$77.48
하루 거래량:
5.34M
Relative Volume:
1.01
시가총액:
$30.17B
수익:
$4.82B
순이익/손실:
$930.40M
주가수익비율:
33.44
EPS:
2.3381
순현금흐름:
$1.43B
1주 성능:
+6.45%
1개월 성능:
+29.01%
6개월 성능:
+17.88%
1년 성능:
-8.74%
1일 변동 폭
$76.50
$78.82
1주일 범위
$71.53
$78.82
52주 변동 폭
$54.11
$89.98
덱스컴 Stock (DXCM) Company Profile
명칭
Dexcom Inc
전화
(858) 200-0200
주소
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
78.19 | 29.57B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
91.25 | 157.63B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
314.01 | 115.59B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
81.98 | 103.60B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
48.96 | 72.39B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.54 | 49.43B | 6.30B | 1.07B | 1.09B | 1.8406 |
덱스컴 Stock (DXCM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2026-01-12 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-12-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 개시 | Evercore ISI | In-line |
| 2025-10-21 | 재개 | Stifel | Buy |
| 2025-09-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-21 | 개시 | Argus | Buy |
| 2025-06-16 | 개시 | Truist | Buy |
| 2025-05-30 | 개시 | Goldman | Buy |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-03 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 개시 | Redburn Atlantic | Neutral |
| 2024-03-12 | 개시 | RBC Capital Mkts | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-04-17 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 개시 | UBS | Buy |
| 2023-01-26 | 개시 | Wolfe Research | Outperform |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-15 | 개시 | Bernstein | Outperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-01-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-28 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2021-01-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-10-02 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 재확인 | Piper Sandler | Overweight |
| 2020-05-14 | 개시 | Wells Fargo | Equal Weight |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-11-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-11-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-10-23 | 개시 | Stifel | Buy |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-19 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-09-12 | 업그레이드 | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 재확인 | Canaccord Genuity | Buy |
| 2018-07-02 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
| 2018-05-03 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-04 | 개시 | Goldman | Sell |
| 2018-04-04 | 개시 | Guggenheim | Neutral |
| 2018-03-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | 다운그레이드 | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 재확인 | Wedbush | Outperform |
모두보기
덱스컴 주식(DXCM)의 최신 뉴스
Dexcom stock (US2521311074): Mizuho lifts target after diabetes study - AD HOC NEWS
DXCM to launch Dexcom Flex CGM system for type 2 diabetes in Germany - MSN
Dexcom bolsters evidence for glucose sensors for Type 2 diabetes - MedTech Dive
Devon Energy Corp stock (US2521311074): Dividend, oil price moves and what matters for investors - AD HOC NEWS
Mizuho raises Dexcom stock price target to $85 on diabetes study - Investing.com
Raymond James Adjusts Price Target on DexCom to $91 From $81, Maintains Strong Buy Rating - marketscreener.com
DexCom Inc (DXCM) Stock Up 5.2% and Still Undervalued -- GF Scor - GuruFocus
DexCom Inc. stock outperforms competitors on strong trading day - MSN
Dexcom reports positive CONNECT data for non-insulin diabetes - MSN
Clinical Wins Boost Dexcom Growth Story In Type 2 DiabetesDexCom (NASDAQ:DXCM) - Benzinga
DexCom, Inc. (DXCM) latest stock news and headlines - Yahoo Finance Singapore
DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes - Yahoo Finance Singapore
Is DexCom stock underperforming the Dow? - MSN
DexCom jumps as new ADA trial data boosts optimism for broader CGM adoption - Quiver Quantitative
Why is DexCom stock surging today? By Investing.com - Investing.com Canada
Mizuho Securities Adjusts DexCom Price Target to $85 From $75, Maintains Outperform Rating - marketscreener.com
Here's why you should retain DexCom stock in your portfolio - MSN
DexCom, Inc. (DXCM): Investor Outlook Reveals 13.92% Potential Upside In Continuous Glucose Monitoring Market - DirectorsTalk Interviews
DexCom (DXCM) Reports Positive Trial Results for Glucose Control in Type 2 Diabetes - GuruFocus
Is It Time To Reassess DexCom (DXCM) After Recent Glucose Monitoring Headlines? - Sahm
Dexcom G7 gave Type 2 adults 5 extra hours a day in range - Stock Titan
Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin - The AI Journal
Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study - Reuters
Assessing DexCom (DXCM) Valuation After Recent Share Price Momentum - Yahoo Finance
Dexcom buys Nutrisense; Insulet rolls out patch pump update - MedTech Dive
Stifel Adjusts Price Target on DexCom to $90 From $85, Maintains Buy Rating - marketscreener.com
Is DexCom Stock Underperforming the Dow? - Barchart
DXCM News | DEXCOM INC (NASDAQ:DXCM) - ChartMill
Here's Why You Should Retain DexCom Stock in Your Portfolio - The Globe and Mail
[Latest] Non-Invasive Blood Glucose Monitoring Devices Market Size to Hit USD 340.49 Million with a Promising CAGR of 25.60% by 2034 - GlobeNewswire Inc.
DexCom (DXCM) Showcases Innovations and Future Plans at ADA Scie - GuruFocus
Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026 - StreetInsider
DexCom vs. Insulet: Growth Trajectories and Valuations for InvestorsNews and Statistics - IndexBox
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026? - Yahoo Finance
Dexcom Reaffirms CGM Benefits for All People With Diabetes and C - GuruFocus
Dexcom to present diabetes study, launch new app, acquire Nutrisense By Investing.com - Investing.com Nigeria
Dexcom to present diabetes study, launch new app, acquire Nutrisense - Investing.com
Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026 – Company AnnouncementFT.com - Financial Times
Elliott strikes Dexcom board settlement after taking stake - MSN
Did FDA-App Recalls and Activist Pressure Just Rewire Dexcom’s (DXCM) Software-Driven Investment Narrative? - Yahoo Finance
Dexcom Inc. stock (US2521311074): customer advisory report and recent trading in focus - AD HOC NEWS
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
The FDA Has Issued a Warning on 2 Popular Glucose Monitors. You Won't Believe Why. - Men's Health
Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience - 01net
Dexcom Releases Customer Advisory Council Report, Outlining Ongo - GuruFocus
Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience – Company AnnouncementFT.com - Financial Times
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $85 - Moomoo
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DexCom - TMX Newsfile
Research Alert: CFRA Maintains Hold Rating On Shares Of Dexcom Inc. - Moomoo
DexCom (NASDAQ: DXCM) director receives 5,605 RSUs equity grant - Stock Titan
덱스컴 (DXCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.07%
자본화:
|
볼륨(24시간):